BML CAPITAL MANAGEMENT LLC
Q2 2023 Form 13-F
ZIONSVILLE, INDIANA
CIK 0001616824
· Institutional investment manager
$111.2M Reported Value Total
BML CAPITAL MANAGEMENT, LLC reports under management (AUM).
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.Reported value
$111.2M
Quarter over quarter
+18.1%
Holdings
31
Top-10 concentration
79.9%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Aryn Sands
Agent
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2023 13F record
Q2 2023 13F filing summary
| Period of report | June 30, 2023 |
|---|---|
| Filed | July 24, 2023 |
| Form | 13F-HR |
| Reported value | $111.2M |
| Positions | 31 |
| Change in reported value | -3.9% |
| New positions | 7 |
| Exited positions | 7 |
| Position turnover | 36.8% |
| Top-10 concentration | 79.9% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 6, 2026
|
18 | $187.6M |
|
Q2 2026 13F
Filed Aug 7, 2026
|
15 | $176.1M |
|
Q1 2026 13F
Filed May 6, 2026
|
15 | $155.8M |
|
Q4 2025 13F
Filed Feb 3, 2026
|
13 | $115.7M |
|
Q3 2025 13F
Filed Nov 10, 2025
|
18 | $109.2M |
|
Q2 2025 13F
Filed Aug 11, 2025
|
23 | $132.2M |
|
Q1 2025 13F
Filed May 7, 2025
|
26 | $123.6M |
|
Q4 2024 13F
Filed Feb 7, 2025
|
25 | $161.0M |
|
Q3 2024 13F
Filed Nov 5, 2024
|
29 | $169.9M |
|
Q2 2024 13F
Filed Aug 7, 2024
|
27 | $140.1M |
|
Q1 2024 13F
Filed Apr 23, 2024
|
30 | $151.7M |
|
Q4 2023 13F
Filed Jan 30, 2024
|
31 | $132.0M |
|
Q3 2023 13F
Filed Oct 23, 2023
|
25 | $108.9M |
|
Q2 2023 13F
Filed Jul 24, 2023
|
31 | $111.2M |
|
Q1 2023 13F
Filed Apr 14, 2023
|
31 | $115.7M |
|
Q4 2022 13F
Filed Feb 13, 2023
|
25 | $104.7M |
Top 20 holdings · Q2 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | BIL SPDR SER TR | $18.4M | 16.52% |
| 2 | SGOV ISHARES TR | $18.1M | 16.29% |
| 3 | CYT CYTEIR THERAPEUTICS INC | $8.5M | 7.6% |
| 4 | AVIR ATEA PHARMACEUTICALS INC | $8.4M | 7.52% |
| 5 | ADVM ADVERUM BIOTECHNOLOGIES INC | $8.2M | 7.38% |
| 6 | PRDS PARDES BIOSCIENCES INC | $6.9M | 6.17% |
| 7 | TALS TALARIS THERAPEUTICS INC | $6.1M | 5.47% |
| 8 | ATHA ATHIRA PHARMA INC | $5.5M | 4.95% |
| 9 | ELYM ELIEM THERAPEUTICS INC | $4.4M | 3.99% |
| 10 | ANF ABERCROMBIE & FITCH CO | $4.4M | 3.98% |
| 11 | ASTC ASTROTECH CORP | $3.1M | 2.81% |
| 12 | ORMP ORAMED PHARMACEUTICALS INC | $3.0M | 2.74% |
| 13 | QNCX QUINCE THERAPEUTICS INC | $2.1M | 1.91% |
| 14 | PASG PASSAGE BIO INC | $1.9M | 1.74% |
| 15 | FBRX FORTE BIOSCIENCES INC | $1.8M | 1.62% |
| 16 | ELVN ENLIVEN THERAPEUTICS INC | $1.5M | 1.36% |
| 17 | ABIO ARCA BIOPHARMA INC | $1.4M | 1.29% |
| 18 | TLYS TILLYS INC | $1.3M | 1.2% |
| 19 | LSTA LISATA THERAPEUTICS INC | $902.2K | 0.81% |
| 20 | VRCA VERRICA PHARMACEUTICALS INC | $865.5K | 0.78% |
Values as reported on the Q2 2023 Form 13F. Every position is in the holdings table below.